Healthcare Industry News:  Pulse Oximetry 

Devices Monitoring

 News Release - June 29, 2006

SPO Medical Launches Compact Wrist-Mounted Oximetry System

PulseOx 7500(TM) is Ideal for Home Pre-Screening of Sleep Apnea Symptoms

WOODLAND HILLS, Calif., June 29 (HSMN NewsFeed) -- SPO Medical Inc. (SPOM.PK), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced the commercial launch of its FDA and CE approved PulseOx 7500(TM), a compact, wrist-mounted oximetry system designed to monitor the vital signs of people experiencing sleep disorder symptoms, such as sleep apnea.

Millions of ordinary people suffer from sleep apnea. Characterized by repeated breathing interruptions in which the brain arouses the person to resume breathing, this sleep disorder interrupts the normal sleep cycle, producing fragmented and poor quality sleep as well as excessive fatigue during the day. People with sleep disorder symptoms typically are referred by their primary care physician to third-party sleep clinics where they are monitored overnight and, depending on the diagnosis, are prescribed medications or other appropriate medical action.

The PulseOx 7500(TM) is ideal for home screening of sleep-related symptoms because it is compact, easy-to-use and gives the wearer maximum comfort, convenience and flexibility. A sensor is placed at the tip of the finger to measure oxygen saturation and heart rate using SPO Medical's patented technology. It is connected to a watch-like, wrist-mounted monitor that collects and stores data over extended periods of time, including overnight while the wearer sleeps. The next morning, data can be downloaded by the family care and general practitioners for analysis via the sleep apnea reporting software and connecting cables that are supplied with each unit. (See for a photo.)

As the first affordable sleep study device for family care and general practitioners, the PulseOx 7500(TM) offers a number of key benefits. Since it can be prescribed directly for an overnight study in the patient's home, the PulseOx 7500(TM) allows the doctor to begin diagnosis almost immediately. Second, it reduces the cost of sleep apnea pre-screening: the PulseOx 7500(TM) is priced at far less than the existing market prices for traditional sleep monitoring equipment and uses long-life batteries for extended periods of constant use, thereby reducing operational costs. Finally, it offers family care and general practitioners a new source of revenue, since they can prescribe and provide the PulseOx 7500(TM) directly to patients, rather than refer them to third-party sleep facilities.

"We're proud to be launching our third portable monitoring device to capture life-saving and/or life-enhancing data within less than two years of introducing our first product," said Michael Braunold, company President and Chief Executive Officer. "Late in 2004, we began shipping our first medically prescribed product, the PulseOx 5500(TM), a spot-check finger pulse oximeter designed for the home care, ambulatory care and emergency medical care markets. Last year, we introduced the Check Mate(TM), a non-medical, sport- version of the product designed to meet the needs of the high altitude performance sports and aviator markets. With the PulseOx 7500(TM), we're offering family care and general practitioners, patients, and insurance companies a cost-effective product to pre-screen patients' vital signs related to sleep disorders in the comfort of the patient's home. With the introduction of the PulseOx 7500(TM), we again demonstrate our commitment to extend SPO Medical's technology applications to meet the diverse needs of health care patients and providers, as well as our shareholders."

About SPO Medical

SPO Medical (SPOM.PK) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit

Safe Harbor:

This document contains forward-looking statements within the meaning of the United States securities laws. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the statements included in this press release. Although SPO Medical believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be achieved. Readers are referred the documents filed by SPO Medical with the Securities and Exchange Commission, including the company's most recent Annual Report on Form 10K-SB and Quarterly Report on Form Q-SB, which identify important risk factors that could cause actual results to differ from those reflected in the forward-looking statements. SPO Medical disclaims any intention or obligation to update or revise any forward- looking statements, which speak only as of the date hereof, whether as a result of new information, future events or otherwise.

Source: SPO Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.